DNA methylation in thoracic neoplasms

Cancer Letters

Volumn 301, Issue 1, 2011, Pages 7-16

  Chen, Chen ^a   Yin, Ni ^a   Yin, Bangliang ^a   Lu, Qianjin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

DNA methylation; DNA methyltransferase; Thoracic neoplasms; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MITHRAMYCIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER MORTALITY; CARCINOGENESIS; DNA METHYLATION; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; ESOPHAGUS CARCINOMA; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SHORT SURVEY; THORAX CANCER; THYMIC EPITHELIAL TUMOR; TRANSCRIPTION REGULATION;

EID: 78650583380     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.017     Document Type: Review

References (130)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
2. Enzinger P.C., Mayer R.J. Esophageal cancer. New Engl. J. Med. 2003, 349:2241-2252.
3. Shimosato Y. Controversies surrounding the subclassification of thymoma. Cancer 1994, 74:542-544.
4. Honglin Y., Jun D., Zhenfeng L., Xia J., Jiandong W., Xiaojun Z. The correlation of the World Health Organization histologic classification of thymic epithelial tumors and its prognosis: a clinicopathologic study of 108 patients from China. Int. J. Surg. Pathol. 2009, 17:255-261.
5. Thomas P.A., Payan-Defais M.J. Epithelial tumours of the thymus. Rev. Pneumol. Clin. 2010, 66:41-51.
6. Zisis C., Rontogianni D., Tzavara C., Stefanaki K., Chatzimichalis A., Loutsidis A., Iliadis K., Kontaxis A., Dosios T., Bellenis I. Prognostic factors in thymic epithelial tumors undergoing complete resection. Ann. Thorac. Surg. 2005, 80:1056-1062.
7. Fang W., Chen W., Chen G., Jiang Y. Surgical management of thymic epithelial tumors: a retrospective review of 204 cases. Ann. Thorac. Surg. 2005, 80:2002-2007.
8. Midthun D.E. Caution: screening for lung cancer. Expert. Rev. Respir. Med. 2009, 3:203-205.
9. Pastorino U. Lung cancer screening. Br. J. Cancer 2010.
10. Tomizawa Y., Wang K.K. Screening, surveillance, and prevention for esophageal cancer. Gastroenterol. Clin. North Am. 2009, 38:59-73. (viii).
11. Kaneko K. Thoracoscopic surgery. Kyobu Geka 2009, 62:718-722.
12. Chen X., Yang C.S. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001, 22:1119-1129.
13. Arasaradnam R.P., Commane D.M., Bradburn D., Mathers J.C. A review of dietary factors and its influence on DNA methylation in colorectal carcinogenesis. Epigenetics 2008, 3:193-198.
14. Vaid M., Floros J. Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review). Oncol Rep. 2009, 21:3-11.
15. Long C., Yin B., Lu Q., Zhou X., Hu J., Yang Y., Yu F., Yuan Y. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007, 25:685-690.
16. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., Liu S., Alder H., Costinean S., Fernandez-Cymering C., Volinia S., Guler G., Morrison C.D., Chan K.K., Marcucci G., Calin G.A., Huebner K., Croce C.M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104:15805-15810.
17. Oki Y., Issa J.P. Review: recent clinical trials in epigenetic therapy. Rev. Recent Clin. Trials 2006, 1:169-182.
18. Kondo Y., Issa J.P. DNA methylation profiling in cancer. Expert Rev. Mol. Med. 2010, 12:e23.
19. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
20. Gan Q., Yoshida T., McDonald O.G., Owens G.K. Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 2007, 25:2-9.
21. Shima K., Nosho K., Baba Y., Cantor M., Meyerhardt J.A., Giovannucci E.L., Fuchs C.S., Ogino S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int. J. Cancer 2010.
22. Deng G., Nguyen A., Tanaka H., Matsuzaki K., Bell I., Mehta K.R., Terdiman J.P., Waldman F.M., Kakar S., Gum J., Crawley S., Sleisenger M.H., Kim Y.S. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int. J. Cancer 2006, 118:2999-3005.
23. Kondo Y., Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metast. Rev. 2004, 23:29-39.
24. Tomizawa Y., Iijima H., Nomoto T., Iwasaki Y., Otani Y., Tsuchiya S., Saito R., Dobashi K., Nakajima T., Mori M. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 2004, 46:305-312.
25. Kim D.S., Kim M.J., Lee J.Y., Kim Y.Z., Kim E.J., Park J.Y. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer 2007, 110:2785-2792.
26. Matsuzaki K., Deng G., Tanaka H., Kakar S., Miura S., Kim Y.S. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin. Cancer Res. 2005, 11:8564-8569.
27. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
28. Tuck-Muller C.M., Narayan A., Tsien F., Smeets D.F., Sawyer J., Fiala E.S., Sohn O.S., Ehrlich M. DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet. Cell Genet. 2000, 89:121-128.
29. Arai E., Kanai Y., Ushijima S., Fujimoto H., Mukai K., Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int. J. Cancer 2006, 119:288-296.
30. Lin T.S., Lee H., Chen R.A., Ho M.L., Lin C.Y., Chen Y.H., Tsai Y.Y., Chou M.C., Cheng Y.W. An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett. 2005, 226:77-84.
31. Chen C., Yin B., Wei Q., Li D., Hu J., Yu F., Lu Q. Aberrant DNA methylation in thymic epithelial tumors. Cancer Invest. 2009, 27:582-591.
32. Pogribny I.P., Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol. Life Sci. 2009, 66:2249-2261.
33. Rauch T.A., Zhong X., Wu X., Wang M., Kernstine K.H., Wang Z., Riggs A.D., Pfeifer G.P. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl. Acad. Sci. USA 2008, 105:252-257.
34. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21:163-167.
35. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomaki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24:132-138.
36. Lee P.N. Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occup. Environ. Med. 2001, 58:145-153.
37. Wang Y., Yu Z., Wang T., Zhang J., Hong L., Chen L. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007, 56:289-294.
38. Alberg A.J., Ford J.G., Samet J.M. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:29S-55S. (second ed.).
39. Fischer J.R., Ohnmacht U., Rieger N., Zemaitis M., Stoffregen C., Manegold C., Lahm H. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 2007, 56:115-123.
40. Kim D.S., Cha S.I., Lee J.H., Lee Y.M., Choi J.E., Kim M.J., Lim J.S., Lee E.B., Kim C.H., Park T.I., Jung T.H., Park J.Y. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer 2007, 58:1-6.
41. Shivapurkar N., Stastny V., Suzuki M., Wistuba, Li L., Zheng Y., Feng Z., Hol B., Prinsen C., Thunnissen F.B., Gazdar A.F. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett. 2007, 247:56-71.
42. Tang X., Khuri F.R., Lee J.J., Kemp B.L., Liu D., Hong W.K., Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 2000, 92:1511-1516.
43. Gasco M., Bell A.K., Heath V., Sullivan A., Smith P., Hiller L., Yulug I., Numico G., Merlano M., Farrell P.J., Tavassoli M., Gusterson B., Crook T. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 2002, 62:2072-2076.
44. Dammann R., Strunnikova M., Schagdarsurengin U., Rastetter M., Papritz M., Hattenhorst U.E., Hofmann H.S., Silber R.E., Burdach S., Hansen G. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur. J. Cancer 2005, 41:1223-1236.
45. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
46. Kersting M., Friedl C., Kraus A., Behn M., Pankow W., Schuermann M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 2000, 18:3221-3229.
47. Maruyama R., Sugio K., Yoshino I., Maehara Y., Gazdar A.F. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004, 100:1472-1477.
48. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl. J. Med. 2000, 343:1350-1354.
49. Buckingham L., Penfield Faber L., Kim A., Liptay M., Barger C., Basu S., Fidler M., Walters K., Bonomi P., Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int. J. Cancer 2010, 126:1630-1639.
50. Chang Y.S., Wang L., Liu D., Mao L., Hong W.K., Khuri F.R., Lee H.Y. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2002, 8:3669-3675.
51. Hsu H.S., Chen T.P., Hung C.H., Wen C.K., Lin R.K., Lee H.C., Wang Y.C. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007, 110:2019-2026.
52. Hsu H.S., Chen T.P., Wen C.K., Hung C.H., Chen C.Y., Chen J.T., Wang Y.C. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J. Pathol. 2007, 213:412-419.
53. Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000, 60:4894-4906.
54. Kim D.H., Kim J.S., Ji Y.I., Shim Y.M., Kim H., Han J., Park J. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 2003, 63:3743-3746.
55. Park J.C., Chae Y.K., Son C.H., Kim M.S., Lee J., Ostrow K., Sidransky D., Hoque M.O., Moon C. Epigenetic silencing of human T (Brachyury homologue) gene in non-small-cell lung cancer. Biochem. Biophys. Res. Commun. 2008, 365:221-226.
56. Dammann R., Takahashi T., Pfeifer G.P. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001, 20:3563-3567.
57. Groeger A.M., Caputi M., Esposito V., De Luca A., Bagella L., Pacilio C., Klepetko W., Giordano G.G., Baldi F., Kaiser H.E., Wolner E., Giordano A. Independent prognostic role of p16 expression in lung cancer. J. Thorac. Cardiovasc. Surg. 1999, 118:529-535.
58. Virmani A.K., Rathi A., Sathyanarayana U.G., Padar A., Huang C.X., Cunnigham H.T., Farinas A.J., Milchgrub S., Euhus D.M., Gilcrease M., Herman J., Minna J.D., Gazdar A.F. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin. Cancer Res. 2001, 7:1998-2004.
59. Zochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001, 61:249-255.
60. Kim D.H., Nelson H.H., Wiencke J.K., Zheng S., Christiani D.C., Wain J.C., Mark E.J., Kelsey K.T. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001, 61:3419-3424.
61. Yanagawa N., Tamura G., Oizumi H., Takahashi N., Shimazaki Y., Motoyama T. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn. J. Cancer Res. 2002, 93:1107-1113.
62. Toyooka S., Maruyama R., Toyooka K.O., McLerran D., Feng Z., Fukuyama Y., Virmani A.K., Zochbauer-Muller S., Tsukuda K., Sugio K., Shimizu N., Shimizu K., Lee H., Chen C.Y., Fong K.M., Gilcrease M., Roth J.A., Minna J.D., Gazdar A.F. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 2003, 103:153-160.
63. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24:2137-2150.
64. Siewert J.R., Stein H.J., Feith M., Bruecher B.L., Bartels H., Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann. Surg. 2001, 234:360-367. (discussion 368-369).
65. Morita M., Kuwano H., Ohno S., Sugimachi K., Seo Y., Tomoda H., Furusawa M., Nakashima T. Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: reference to smoking, drinking and family history. Int. J. Cancer 1994, 58:207-210.
66. An J.Y., Fan Z.M., Zhuang Z.H., Qin Y.R., Gao S.S., Li J.L., Wang L.D. Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province. World J. Gastroenterol. 2004, 10:3365-3368.
67. Ito S., Ohga T., Saeki H., Nakamura T., Watanabe M., Tanaka S., Kakeji Y., Maehara Y. p53 Mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. Int. J. Cancer 2005, 113:22-28.
68. Kuwano H., Kato H., Miyazaki T., Fukuchi M., Masuda N., Nakajima M., Fukai Y., Sohda M., Kimura H., Faried A. Genetic alterations in esophageal cancer. Surg. Today 2005, 35:7-18.
69. Lo P.H., Xie D., Chan K.C., Xu F.P., Kuzmin I., Lerman M.I., Law S., Chua D., Sham J., Lung M.L. Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage. Cancer Lett. 2007, 257:199-205.
70. Yamaguchi S., Kato H., Miyazaki T., Sohda M., Kimura H., Ide M., Asao T., Kuwano H. RASSF1A gene promoter methylation in esophageal cancer specimens. Dis. Esophagus 2005, 18:253-256.
71. Liu Z., Zhang L., Ding F., Li J., Guo M., Li W., Wang Y., Yu Z., Zhan Q., Wu M. 5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett. 2005, 230:271-283.
72. Zhao B.J., Tan S.N., Cui Y., Sun D.G., Ma X. Aberrant promoter methylation of the TPEF gene in esophageal squamous cell carcinoma. Dis. Esophagus 2008, 21:582-588.
73. Schulmann K., Sterian A., Berki A., Yin J., Sato F., Xu Y., Olaru A., Wang S., Mori Y., Deacu E., Hamilton J., Kan T., Krasna M.J., Beer D.G., Pepe M.S., Abraham J.M., Feng Z., Schmiegel W., Greenwald B.D., Meltzer S.J. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005, 24:4138-4148.
74. Wu D.L., Sui F.Y., Jiang X.M., Jiang X.H. Methylation in esophageal carcinogenesis. World J. Gastroenterol. 2006, 12:6933-6940.
75. Kawakami K., Brabender J., Lord R.V., Groshen S., Greenwald B.D., Krasna M.J., Yin J., Fleisher A.S., Abraham J.M., Beer D.G., Sidransky D., Huss H.T., Demeester T.R., Eads C., Laird P.W., Ilson D.H., Kelsen D.P., Harpole D., Moore M.B., Danenberg K.D., Danenberg P.V., Meltzer S.J. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 2000, 92:1805-1811.
76. Jin Z., Cheng Y., Olaru A., Kan T., Yang J., Paun B., Ito T., Hamilton J.P., David S., Agarwal R., Selaru F.M., Sato F., Abraham J.M., Beer D.G., Mori Y., Shimada Y., Meltzer S.J. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int. J. Cancer 2008, 123:2331-2336.
77. Hardie L.J., Darnton S.J., Wallis Y.L., Chauhan A., Hainaut P., Wild C.P., Casson A.G. p16 Expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 2005, 217:221-230.
78. Zou H., Osborn N.K., Harrington J.J., Klatt K.K., Molina J.R., Burgart L.J., Ahlquist D.A. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol. Biomar. Prev. 2005, 14:830-834.
79. Tsunoda S., Smith E., De Young N.J., Wang X., Tian Z.Q., Liu J.F., Jamieson G.G., Drew P.A. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncol Rep. 2009, 21:1067-1073.
80. Steiner F.A., Hong J.A., Fischette M.R., Beer D.G., Guo Z.S., Chen G.A., Weiser T.S., Kassis E.S., Nguyen D.M., Lee S., Trepel J.B., Schrump D.S. Sequential 5-aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 2005, 24:2386-2397.
81. Eads C.A., Lord R.V., Wickramasinghe K., Long T.I., Kurumboor S.K., Bernstein L., Peters J.H., DeMeester S.R., DeMeester T.R., Skinner K.A., Laird P.W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001, 61:3410-3418.
82. Wang Y., Fang M.Z., Liao J., Yang G.Y., Nie Y., Song Y., So C., Xu X., Wang L.D., Yang C.S. Hypermethylation-associated inactivation of retinoic acid receptor beta in human esophageal squamous cell carcinoma. Clin. Cancer Res. 2003, 9:5257-5263.
83. Nie Y., Liao J., Zhao X., Song Y., Yang G.Y., Wang L.D., Yang C.S. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 2002, 23:1713-1720.
84. Lardinois D., Rechsteiner R., Lang R.H., Gugger M., Betticher D., von Briel C., Krueger T., Ris H.B. Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors. Ann. Thorac. Surg. 2000, 69:1550-1555.
85. Quintanilla-Martinez L., Wilkins E.W., Choi N., Efird J., Hug E., Harris N.L. Thymoma: histologic subclassification is an independent prognostic factor. Cancer 1994, 74:606-617.
86. Zettl A., Strobel P., Wagner K., Katzenberger T., Ott G., Rosenwald A., Peters K., Krein A., Semik M., Muller-Hermelink H.K., Marx A. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am. J. Pathol. 2000, 157:257-266.
87. Hirose Y., Kondo K., Takizawa H., Nagao T., Nakagawa Y., Fujino H., Toba H., Kenzaki K., Sakiyama S., Tangoku A. Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 2009, 64:155-159.
88. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
89. Hsiung D.T., Marsit C.J., Houseman E.A., Eddy K., Furniss C.S., McClean M.D., Kelsey K.T. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007, 16:108-114.
90. Wilson A.S., Power B.E., Molloy P.L. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 2007, 1775:138-162.
91. Riggs A.D., Jones P.A. 5-Methylcytosine, gene regulation, and cancer. Adv. Cancer Res. 1983, 40:1-30.
92. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
93. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
94. Hibi K., Takahashi T., Yamakawa K., Ueda R., Sekido Y., Ariyoshi Y., Suyama M., Takagi H., Nakamura Y. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 1992, 7:445-449.
95. Saito K., Kawakami K., Matsumoto I., Oda M., Watanabe G., Minamoto T. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2418-2426.
96. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1:239-259.
97. Piyathilake C.J., Frost A.R., Bell W.C., Oelschlager D., Weiss H., Johanning G.L., Niveleau A., Heimburger D.C., Grizzle W.E. Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression. Hum. Pathol. 2001, 32:856-862.
98. Piyathilake C.J., Henao O., Frost A.R., Macaluso M., Bell W.C., Johanning G.L., Heimburger D.C., Niveleau A., Grizzle W.E. Race- and age-dependent alterations in global methylation of DNA in squamous cell carcinoma of the lung (United States). Cancer Causes Control 2003, 14:37-42.
99. Rountree M.R., Bachman K.E., Herman J.G., Baylin S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001, 20:3156-3165.
100. Kim H., Kwon Y.M., Kim J.S., Han J., Shim Y.M., Park J., Kim D.H. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006, 107:1042-1049.
101. Shieh Y.S., Shiah S.G., Jeng H.H., Lee H.S., Wu C.W., Chang L.C. DNA methyltransferase 1 expression and promoter methylation of E-cadherin in mucoepidermoid carcinoma. Cancer 2005, 104:1013-1021.
102. Girault I., Tozlu S., Lidereau R., Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 2003, 9:4415-4422.
103. Lin R.K., Hsu H.S., Chang J.W., Chen C.Y., Chen J.T., Wang Y.C. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007, 55:205-213.
104. Vallbohmer D., Brabender J., Yang D., Schneider P.M., Metzger R., Danenberg K.D., Holscher A.H., Danenberg P.V. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin. Lung Cancer 2006, 8:39-44.
105. Kassis E.S., Zhao M., Hong J.A., Chen G.A., Nguyen D.M., Schrump D.S. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J. Thorac. Cardiovasc. Surg. 2006, 131:298-306.
106. Yang X., Phillips D.L., Ferguson A.T., Nelson W.G., Herman J.G., Davidson N.E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001, 61:7025-7029.
107. Lin R.K., Hsu C.H., Wang Y.C. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 2007, 18:1157-1164.
108. Archer S.Y., Hodin R.A. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 1999, 9:171-174.
109. Buckstein R., Yee K., Wells R.A. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer Treat. Rev. 2010.
110. Kantarjian H.M., Giles F.J., Greenberg P.L., Paquette R.L., Wang E.S., Gabrilove J.L., Garcia-Manero G., Hu K., Franklin J.L., Berger D.P. Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010.
111. Fischer J.R., Ohnmacht U., Rieger N., Zemaitis M., Stoffregen C., Kostrzewa M., Buchholz E., Manegold C., Lahm H. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54:109-116.
112. Guo M., Ren J., House M.G., Qi Y., Brock M.V., Herman J.G. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 2006, 12:4515-4522.
113. Kim Y.T., Park J.Y., Jeon Y.K., Park S.J., Song J.Y., Kang C.H., Sung S.W., Kim J.H. Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis. Esophagus 2009, 22:143-150.
114. Ito S., Ohga T., Saeki H., Watanabe M., Kakeji Y., Morita M., Yamada T., Maehara Y. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma. Anticancer Res. 2007, 27:3345-3353.
115. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., Zangemeister-Wittke U., Stahel R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003, 10:356-364.
116. Brabender J., Arbab D., Huan X., Vallbohmer D., Grimminger P., Ling F., Neiss S., Bollschweiler E., Schneider P.M., Holscher A.H., Metzger R. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer. Ann. Surg. Oncol. 2009, 16:1378-1383.
117. Kuroki T., Trapasso F., Yendamuri S., Matsuyama A., Alder H., Mori M., Croce C.M. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin. Cancer Res. 2003, 9:1441-1445.
118. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., Kelsey K.T. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum. Pathol. 2005, 36:768-776.
119. Lee M.N., Tseng R.C., Hsu H.S., Chen J.Y., Tzao C., Ho W.L., Wang Y.C. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 2007, 13:832-838.
120. Tischoff I., Hengge U.R., Vieth M., Ell C., Stolte M., Weber A., Schmidt W.E., Tannapfel A. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 2007, 56:1047-1053.
121. Ramirez J.L., Sarries C., de Castro P.L., Roig B., Queralt C., Escuin D., de Aguirre I., Sanchez J.M., Manzano J.L., Margeli M., Sanchez J.J., Astudillo J., Taron M., Rosell R. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 2003, 193:207-216.
122. Virmani A., Rathi A., Sugio K., Sathyanarayana U.G., Toyooka S., Kischel F.C., Tonk V., Padar A., Takahashi T., Roth J.A., Euhus D.M., Minna J.D., Gazdar A.F. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int. J. Cancer 2003, 106:198-204.
123. Watanabe F., Takao M., Inoue K., Nishioka J., Nobori T., Shiraishi T., Kaneda M., Sakai T., Yada I., Shimpo H. Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma. Lung Cancer 2009, 63:39-44.
124. Corn P.G., Summers M.K., Fogt F., Virmani A.K., Gazdar A.F., Halazonetis T.D., El-Deiry W.S. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003, 24:47-51.
125. Shibata Y., Haruki N., Kuwabara Y., Ishiguro H., Shinoda N., Sato A., Kimura M., Koyama H., Toyama T., Nishiwaki T., Kudo J., Terashita Y., Konishi S., Sugiura H., Fujii Y. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 2002, 23:1695-1699.
126. Nie Y., Yang G., Song Y., Zhao X., So C., Liao J., Wang L.D., Yang C.S. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001, 22:1615-1623.
127. Ito M., Ito G., Kondo M., Uchiyama M., Fukui T., Mori S., Yoshioka H., Ueda Y., Shimokata K., Sekido Y. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett. 2005, 225:131-139.
128. Yi Lo P.H., Chung Leung A.C., Xiong W., Law S., Duh F.M., Lerman M.I., Stanbridge E.J., Lung M.L. Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett. 2006, 234:184-192.
129. Fumoto S., Hiyama K., Tanimoto K., Noguchi T., Hihara J., Hiyama E., Nishiyama M. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Cancer Lett. 2009, 274:25-32.
130. Shimizu K., Itsuzaki Y., Onishi M., Fujii H., Honoki K., Tsujiuchi T. Reduced expression of the Tslc1 gene and its aberrant DNA methylation in rat lung tumors. Biochem. Biophys. Res. Commun. 2006, 347:358-362.